Renal cell carcinoma (RCC) is a tumor where new biological knowledge has changed the landscape: indeed, antiangiogenic agents and immunotherapy are changing the natural history of disease. New discoveries in targeted therapy are paralleled by those in immunotherapy: the treatment paradigm continues to evolve. The currently available drugs do not benefit every patient equally. Biological factors particular to certain individuals have a clear effect on this variation in response. Given the increasing number of treatment options but without the same benefit for every patient, the patient selection in the future will be the key. Predictive biomarkers are required for treatment personalization. Multidisciplinarity is important also for the emerging role of cytoreductive nephrectomy and metastasectomy in selected cases. The future is represented by new drugs, new combinations, and the development of precision therapy.
Renal Cancer
C. Porta
2021-01-01
Abstract
Renal cell carcinoma (RCC) is a tumor where new biological knowledge has changed the landscape: indeed, antiangiogenic agents and immunotherapy are changing the natural history of disease. New discoveries in targeted therapy are paralleled by those in immunotherapy: the treatment paradigm continues to evolve. The currently available drugs do not benefit every patient equally. Biological factors particular to certain individuals have a clear effect on this variation in response. Given the increasing number of treatment options but without the same benefit for every patient, the patient selection in the future will be the key. Predictive biomarkers are required for treatment personalization. Multidisciplinarity is important also for the emerging role of cytoreductive nephrectomy and metastasectomy in selected cases. The future is represented by new drugs, new combinations, and the development of precision therapy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
